Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib

American Journal of Pathology

Volumn 169, Issue 4, 2006, Pages 1238-1250

  Sato, Yasunori ^a   Harada, Kenichi ^a   Furubo, Shinichi ^b   Kizawa, Kazuo ^b   Sanzen, Takahiro ^b   Yasoshima, Mitsue ^a   Ozaki, Satoru ^a   Isse, Kumiko ^a   Sasaki, Motoko ^a   Nakanuma, Yasuni ^a,c  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE DUCT DILATATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; EPITHELIUM CELL; INTRAHEPATIC BILE DUCT; KIDNEY CYST; KIDNEY POLYCYSTIC DISEASE; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; LESIONS AND DEFECTS; LIVER; LIVER DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; BILE DUCTS, INTRAHEPATIC; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; LIVER; LIVER DISEASES; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 7; POLYCYSTIC KIDNEY DISEASES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33947306782     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051136     Document Type: Article

References (48)

1. Nakanuma Y, Terada T, Ohta G, Kurachi M, Matsubara F: Caroli's disease in congenital hepatic fibrosis and infantile polycystic disease. Liver 1982, 2:346-354
2. Sanzen T, Harada K, Yasoshima M, Kawamura Y, Ishibashi M, Nakanuma Y: Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis. Am J Pathol 2001, 158:1605-1612
3. Wilson PD: Polycystic kidney disease. N Engl J Med 2004, 350:151-164
4. Harris PC, Rossetti S: Molecular genetics of autosomal recessive polycystic kidney disease. Mol Genet Metab 2004, 81:75-85
5. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC: The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002, 30:259-269
6. Onuchic LF, Furu L, Nagasawa Y, Hou X, Eggermann T, Ren Z, Bergmann C, Senderek J, Esquivel E, Zeltner R, Rudnik-Schoneborn S, Mrug M, Sweeney W, Avner ED, Zerres K, Guay-Woodford LM, Somlo S, Germino GG: PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002, 70:1305-1317
7. Bergmann C, Senderek J, Kupper F, Schneider F, Dornia C, Windelen E, Eggermann T, Rudnik-Schoneborn S, Kirfel J, Furu L, Onuchic LF, Rossetti S, Harris PC, Somlo S, Guay-Woodford L, Germino GG, Moser M, Buttner R, Zerres K: PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat 2004, 23:453-463
8. Zhang MZ, Mai W, Li C, Cho SY, Hao C, Moeckel G, Zhao R, Kim I, Wang J, Xiong H, Wang H, Sato Y, Wu Y, Nakanuma Y, Lilova M, Pei Y, Harris RC, Li S, Coffey RJ, Sun L, Wu D, Chen XZ, Breyer MD, Zhao ZJ, McKanna JA, Wu G: PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci USA 2004, 101:2311-2316
9. Wang S, Luo Y, Wilson PD, Witman GB, Zhou J: The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area. J Am Soc Nephrol 2004, 15:592-602
10. Ward CJ, Yuan D, Masyuk TV, Wang X, Punyashthiti R, Whelan S, Bacallao R, Torra R, LaRusso NF, Torres VE, Harris PC: Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet 2003, 12:2703-2710
11. Masyuk TV, Huang BQ, Masyuk AI, Ritman EL, Torres VE, Wang X, Harris PC, Larusso NF: Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol 2004, 165:1719-1730
12. Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, Punyashthiti R, Ritman EL, Torres VE, Harris PC, LaRusso NF: Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 2003, 125:1303-1310
13. Moser M, Matthiesen S, Kirfel J, Schorle H, Bergmann C, Senderek J, Rudnik-Schoneborn S, Zerres K, Buettner R: A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2005, 41:1113-1121
14. MacRae Dell K, Nemo R, Sweeney Jr WE, Avner ED: EGF-related growth factors in the pathogenesis of murine ARPKD. Kidney Int 2004, 65:2018-2029
15. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner ED: Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 1998, 101:935-939
16. Sweeney Jr WE, Avner ED: Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease. Am J Physiol 1998, 275:F387-F394
17. Marfella-Scivittaro C, Quinones A, Orellana SA: cAMP-dependent protein kinase and proliferation differ in normal and polycystic kidney epithelia. Am J Physiol 2002, 282:C693-C707
18. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000, 57:1460-1471
19. Hanaoka K, Guggino WB: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000, 11:1179-1187
20. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED: Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 2000, 57:339-340
21. Sweeney Jr WE, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED: Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 2003, 64:1310-1319
22. Torres VE, Sweeney Jr WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED: EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003, 64:1573-1579
23. Gattone II VH, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003, 9:1323-1326
24. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone II VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004, 10:363-364
25. Wang X, Gattone II V, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005, 16:846-851
26. Torres VE, Sweeney Jr WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED: Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int 2004, 66:1766-1773
27. Wells A: EGF receptor. Int J Biochem Cell Biol 1999, 31:637-643
28. Sato Y, Harada K, Kizawa K, Sanzen T, Furubo S, Yasoshima M, Ozaki S, Ishibashi M, Nakanuma Y: Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease. Am J Pathol 2005, 166:49-60
29. Kawamura Y, Yoshida K, Nakanuma Y: Primary culture of rabbit gallbladder epithelial cells in collagen gel matrix. Lab Invest 1989, 61:350-356
30. Frankfurt OS, Krishan A: Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J Histochem Cytochem 2001, 49:369-378
31. Baselga J, Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 2000, 60(Suppl 1):32-41
32. Herbst RS, Fukuoka M, Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004, 4:956-965
33. Pinto RB, Lima JP, da Silveira TR, Scholl JG, de Mello ED, Silva G: Caroli's disease: report of 10 cases in children and adolescents in southern Brazil. J Pediatr Surg 1998, 33:1531-1535
34. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A: Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003, 195:139-150
35. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H: Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004, 90:236-244
36. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G: ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002, 98:463-469
37. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and trans-activation by insulin-like growth factor receptor. J Biol Chem 2002, 277:27643-27650
38. Schuster N, Krieglstein K: Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002, 307:1-14
39. Pi X, Yan C, Berk BC: Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res 2004, 94:362-369
40. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG, Kayahara M, Dixon J, Boot-Handford RP, Cartwright EJ, Mayer U, Tournier C: Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cel Biol 2005, 25:336-345
41. Alpini G, McGill JM, Larusso NF: The pathobiology of biliary epithelia. Hepatology 2002, 35:1256-1268
42. Bernatchez PN, Allen BG, Gelinas DS, Guillemette G, Sirois MG: Regulation of VEGF-induced endothelial cell PAF synthesis: role of p42/44 MAPK, p38 MAPK and PI3K pathways. Br J Pharmacol 2001, 134:1253-1262
43. Nichols MT, Gidey E, Matzakos T, Dahl R, Stiegmann G, Shah RJ, Grantham JJ, Fitz JG, Doctor RB: Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004, 40:836-846
44. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, Bedossa P: Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999, 30:968-976
45. Sedlaczek N, Jia JD, Bauer M, Herbst H, Ruehl M, Hahn EG, Schuppan D: Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 2001, 158:1239-1244
46. Ozaki S, Sato Y, Yasoshima M, Harada K, Nakanuma Y: Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis. Liver Int 2005, 25:817-828
47. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn Jr WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R: United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10:1212-1218
48. Torres VE: Therapies to slow polycystic kidney disease. Nephron Exp Nephrol 2004, 98:e1-e7